Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

$AVXL next target is the 52-week high of

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
InsiderFinancial Member Profile
Member Level 
Followed By 147
Posts 808
Boards Moderated 1
Alias Born 07/15/16
160x600 placeholder
Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People wit... GlobeNewswire Inc. - 1/11/2021 7:00:00 AM
Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect Conference GlobeNewswire Inc. - 1/6/2021 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2021 2:28:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2021 2:26:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2021 2:25:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2021 2:23:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2021 2:20:54 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/28/2020 5:29:22 PM
Annual Report (10-k) Edgar (US Regulatory) - 12/28/2020 5:28:26 PM
Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates GlobeNewswire Inc. - 12/28/2020 7:00:00 AM
Biotech Report; Upcoming FDA Reviews and Promising Pipelines InvestorsHub NewsWire - 12/22/2020 8:20:00 AM
Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020 GlobeNewswire Inc. - 12/22/2020 7:00:00 AM
Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data hosted by Ladenburg Thal... GlobeNewswire Inc. - 12/21/2020 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/15/2020 7:09:21 AM
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. P... GlobeNewswire Inc. - 12/15/2020 7:00:00 AM
Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (b... GlobeNewswire Inc. - 11/30/2020 7:00:00 AM
Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference GlobeNewswire Inc. - 11/25/2020 7:00:00 AM
Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Demen... GlobeNewswire Inc. - 11/6/2020 10:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2020 7:05:29 AM
Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-... GlobeNewswire Inc. - 10/15/2020 7:00:10 AM
Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial GlobeNewswire Inc. - 9/10/2020 7:00:10 AM
Anavex Life Sciences to Present at Upcoming Global Healthcare Conferences GlobeNewswire Inc. - 9/8/2020 7:00:10 AM
Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for C... GlobeNewswire Inc. - 8/19/2020 7:00:10 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2020 4:11:04 PM
Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business Updates GlobeNewswire Inc. - 8/6/2020 7:00:10 AM
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences